Our Medicines

Through development and commercialization partnerships, Sosei Heptares has already delivered two products to treat chronic obstructive pulmonary disease (COPD) and an emergency contraceptive to market. The legacy Novartis franchise continues to generate significant and stable revenue streams that enable further growth of the business.


Ultibro® Breezhaler®
(EU and RoW – launched 2014)
(China - launched 2019)

Utibron™ Neohaler®
(US – launched 2017)

Indication:  COPD
Partner:  Novartis

Seebri® Breezhaler®
(EU and RoW – launched 2012)
(China - launched 2019)

Seebri™ Neohaler®
(US – launched late 2017)

Indication:  COPD
Partner:  Novartis

NorLevo® 0.75mg
(Japan – launched 2011)

Indication:  Emergency contraception
Partner:  ASKA Pharmaceutical Co

ORAVI®
(Japan - launching February 2019)

Indication:  Oropharyngeal candidiasis
Partner:  FUJIFILM Toyama Chemical Co., Ltd.